The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Optimal PCR responses and survival of patients with CBF-AML treated with FLAG-IDA or FLAG-GO
Jayastu Senapati, MBBS, MD, MD Anderson Cancer Center, Houston, TX, comments on the results of a study investigating the factors affecting early and late optimal PCR responses and survival in patients with core binding factor acute myeloid leukemia (CBF-AML) treated with fludarabine, cytarabine, and GCSF with idarubicin (FLAG-IDA), or with gemtuzumab ozogamicin (FLAG-GO). The study found that patients treated with FLAG-GO had a better optimal PCR response both after the first cycle and the last cycle of therapy, and also had a better relapse-free survival (RFS) and overall survival (OS). In addition, kinase mutations were not found to have a significant impact on FLAG-based treatment regimens. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
